Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.
July 15 2019 - 8:30AM
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with
a customer-centric approach focused on delivering breakthrough
products, today announced it has further strengthened and
diversified its Board with the appointments of Peter Farrell, Ph.D.
and Karah Parschauer, J.D. effective today.
“I am pleased to welcome Peter and Karah to the
Evolus Board of Directors. They both bring a wealth of experience
to the company,” said Vik Malik, Chairman of the Board.
“Peter Farrell is highly regarded as a visionary in the
healthcare industry. His intimate understanding of how to scale and
build public companies will be a significant asset to Evolus.
Karah Parschauer has a proven track record of success within the
life sciences industry, including medical aesthetics. She’s built
and led corporate development, legal and compliance operations, all
of which will be invaluable in guiding the company forward.”
Dr. Farrell commented, “I am pleased to join the
Evolus Board of Directors at such a pivotal moment in the company’s
history. I believe the company’s lead product Jeuveau™ has the
potential to transform the aesthetics industry. I look
forward to leveraging my experience to support the company’s goal
of achieving the number two U.S. market position for Jeuveau™
within the next two years.”
Ms. Parschauer added, “Evolus just launched
Jeuveau™ in one of the fastest growing and most competitive markets
in healthcare, which makes this company’s story and goals quite
compelling. I look forward to working with the Board of Directors
and contributing my extensive legal and corporate governance
experience in the aesthetics market.”
The Evolus Board of Directors is now comprised
of nine directors, six of whom are considered independent in
accordance with the rules of Nasdaq.
Dr. Peter Farrell is an industry veteran with
extensive public company experience having successfully taken
companies from inception through full scale commercialization. He
is the Founder and current Chairman of the Board of ResMed (NYSE:
RMD) (ASX: RMD), where he served as its Chief Executive Officer
until 2014. Prior to founding ResMed, Dr. Farrell served as Vice
President, Research and Development at various subsidiaries of
Baxter International, Inc. and served as Managing Director of the
Baxter Center for Medical Research Pty Ltd, a Baxter subsidiary. He
previously served as Foundation Director of the Graduate School for
Biomedical Engineering at the University of New South Wales where
he currently serves as a Visiting Professor. Dr. Farrell is
on the Visiting Committee of the Harvard/MIT Health Sciences &
Technology Program and currently serves on the MIT Dean of
Engineering’s Advisory Council. Dr. Farrell is on the board
of Arcturus Therapeutics Ltd (NASDAQ: ARCT), serves as the Chairman
of WaveGuide and was previously a director of NuVasive, Inc.
(NASDAQ: NUVA). Dr. Farrell holds a B.E. in chemical engineering
with honors from the University of Sydney, an S.M. in chemical
engineering from the Massachusetts Institute of Technology, a Ph.D.
in chemical engineering and bioengineering from the University of
Washington Seattle and a D.Sc. from the University of New South
Wales.
Karah Parschauer has extensive experience
leading biotech companies through various phases of growth and
transformation. Ms. Parschauer is currently Executive Vice
President, General Counsel and Secretary to the Board of Directors
at Ultragenyx Pharmaceutical (NASDAQ: RARE), a commercial stage
biotechnology company focused on the treatment of rare genetic
diseases, where she leads the Company’s legal, compliance and
government affairs departments. Prior to Ultragenyx, Ms.
Parschauer was a senior leader at Allergan for 11 years, most
recently as the head of legal and compliance for Allergan’s Medical
Aesthetic division. Ms. Parschauer currently serves on the board of
Arcturus Therapeutics Ltd (NASDAQ: ARCT). Ms. Parschauer graduated
from Miami University in Oxford, OH, and earned a J.D. from Harvard
Law School.
About Evolus,
Inc.Evolus is a performance beauty company with a
customer-centric approach focused on delivering breakthrough
products. In 2019, the U.S. Food and Drug
Administration approved Jeuveau™ (prabotulinumtoxinA-xvfs),
the first and only neurotoxin dedicated exclusively to aesthetics
and manufactured in a state-of-the-art facility using Hi-Pure™
technology. Jeuveau™ is powered by Evolus' unique
technology platform and is designed to transform the aesthetic
market by eliminating the friction points existing for customers
today. Visit us at: www.evolus.com.
Forward-Looking
StatementsStatements made in this release that relate to
the status of regulatory processes, future plans, events, prospects
or performance are forward-looking statements as defined under the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical fact, are statements that could
be deemed forward-looking statements, including statements
containing the words “planned,” “expect,” “believes,” “strategy,”
“opportunity,” “anticipates,” “outlook,” “designed,” and similar
words. While these forward-looking statements are based on the
current expectations and beliefs of management, such
forward-looking statements are subject to a number of risks,
uncertainties, assumptions and other factors that could cause
actual results to differ materially from the expectations expressed
in this release, including the risks and uncertainties disclosed in
Evolus’ periodic filings with the Securities and Exchange
Commission, including factors described in the section entitled
”Risk Factors” in its Annual Report on Form 10-K for the year
ended December 31, 2018 and our Quarterly Report on Form
10-Q for the quarter ended March 31, 2019 as filed with
the Securities and Exchange Commission on March 20,
2019 and May 1, 2019, respectively, all of which are available
online at www.sec.gov. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof. Except as required by
law, Evolus undertakes no obligation to update or revise
any forward-looking statements to reflect new information, changed
circumstances or unanticipated events.
Jeuveau™ is a trademark of Evolus,
Inc.Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co., Ltd
Evolus, Inc. Contacts:
Investor Contacts: Ashwin Agarwal, Evolus, Inc. Vice
President, Finance, Investor Relations & Treasury Tel:
+1-949-284-4559 Email: IR@Evolus.com
Media Contacts: Crystal Muilenburg, Evolus, Inc. Vice
President, Corporate Communications & Public Relations
Tel: +1-949-284-4506 Email: media@evolus.com
Resmed (ASX:RMD)
Historical Stock Chart
From Apr 2024 to May 2024
Resmed (ASX:RMD)
Historical Stock Chart
From May 2023 to May 2024